Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL6065660 | 0.94 | TSHR (0.41) | TSHRALDH1A1 | |
| SCHEMBL14983 | 0.94 | TSHR (0.43) | TSHRALDH1A1 | |
| Hydrochloric Acid SCHEMBL129148 | 0.92 | TSHR (0.42) | TSHRALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL5702351 | 0.92 | TSHR (0.42) | TSHRALDH1A1 | |
| Methyl Alcohol SCHEMBL21326729 | 0.92 | TSHR (0.42) | TSHRALDH1A1 | |
| Iodide SCHEMBL1302038 | 0.92 | TSHR (0.42) | TSHRALDH1A1 | |
| Bromide SCHEMBL1302921 | 0.92 | TSHR (0.42) | TSHRALDH1A1 | |
| Fluoride SCHEMBL1303213 | 0.92 | TSHR (0.42) | TSHRALDH1A1 | |
| Methacrylic Acid SCHEMBL28158609 | 0.91 | TSHR (0.34) | TSHRALDH1A1 | |
| Chloromethane SCHEMBL127391 | 0.90 | TSHR (0.41) | TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-63188621-A | — | — | None | — | — | JP | disclosed |
| CN-102333840-B | Treatment fluids comprising relative permeability modifiers and methods of use | 哈利伯顿能源服务公司 | 2016-08-31 | — | — | CN | disclosed |
| CN-102333840-A | Treatment fluids comprising relative permeability modifiers and methods of use | HALLIBURTON ENERGY SERV INC | 2012-01-25 | — | — | CN | disclosed |
| CN-100528847-C | Uv absorber compositions comprising a hydroxyphenyltriazine compound | CIBA SC HOLDING AG (CH) | 2009-08-19 | — | — | CN | disclosed |
| US-7154001-B2 | Formate salt of O-desmethyl-venlafaxine | WYETH (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060058552-A1 | Novel formate salt of O-desmethyl-venlafaxine | WYETH (US) | 2006-03-16 | — | — | US | disclosed |
| US-7001920-B2 | Formate salt of O-desmethyl-venlafaxine | WYETH (US) | 2006-02-21 | — | — | US | disclosed |
| CN-1658861-A | Novel formate salt of o-desmethyl-venlafaxine | WYETH CORP (US) | 2005-08-24 | — | — | CN | disclosed |
| EP-1519720-A2 | NOVEL FORMATE SALT OF O-DESMETHYL-VENLAFAXINE | Wyeth (US) | 2005-04-06 | — | — | EP | disclosed |
| US-20030236309-A1 | Novel formate salt of O-desmethyl-venlafaxine | WYETH | 2003-12-25 | — | — | US | disclosed |
| WO-2003103603-A2 | NOVEL FORMATE SALT OF O-DESMETHYL-VENLAFAXINE | WYETH (US) | 2003-12-18 | — | — | WO | disclosed |
| US-20030087913-A1 | Solid pharmaceutical agent formulation for a piperazine urea derivative | SCHERING AG (DE) | 2003-05-08 | — | — | US | disclosed |
| EP-0612328-A1 | POLYMERISABLE COMPOSITIONS. | ICI PLC (GB) | 1994-08-31 | — | — | EP | disclosed |
| EP-0563299-A4 | BALANCED CHARGE POLYMER AND HYDROPHILIC CONTACT LENS MANUFACTURED THEREFROM | CESKOSLOVENSKA AKADEMIE VED (CS) | 1994-07-20 | — | — | EP | disclosed |
| EP-0563299-A1 | BALANCED CHARGE POLYMER AND HYDROPHILIC CONTACT LENS MANUFACTURED THEREFROM | Hydron Limited (GB) | 1993-10-06 | — | — | EP | disclosed |
| WO-1993010159-A1 | POLYMERISABLE COMPOSITIONS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-05-27 | — | — | WO | disclosed |
| WO-1992011301-A1 | BALANCED CHARGE POLYMER AND HYDROPHILIC CONTACT LENS MANUFACTURED THEREFROM | ALLERGAN, INC. (US) | 1992-07-09 | — | — | WO | disclosed |
| JP-S63188621-A | FLAVOR ORAL PREPARATION | TAISHO PHARMACEUT CO LTD | 1988-08-04 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087913-A1 | Solid pharmaceutical agent formulation for a piperazine urea derivative | SLC14A1, UTS2R, SP1 | TSHR 2536/4885ALDH1A1 1795/4885 |
| US-20060058552-A1 | Novel formate salt of O-desmethyl-venlafaxine | SLC6A3, SLC6A2, SLC6A4 | TSHR 3141/4885ALDH1A1 607/4885 |
| US-20030236309-A1 | Novel formate salt of O-desmethyl-venlafaxine | SLC6A3, SLC6A2, SLC6A4 | TSHR 3141/4885ALDH1A1 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.